Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection

被引：0

作者：

Bazinet, Michel ^{[1
]}

Pantea, Victor ^{[2
]}

Cebotarescu, Valentin ^{[2
]}

Cojuhari, Lilia ^{[3
]}

Jimbei, Paulina ^{[3
]}

Albrecht, Jeffrey ^{[4
]}

Schmid, Peter ^{[4
]}

Krawczyk, Adalbert ^{[5
]}

Karimzadeh, Hadi ^{[6
]}

Roggendorf, Michael ^{[6
]}

Valliant, Andrew ^{[1
]}

机构：

[1] Replicor Inc, Montreal, PQ, Canada

[2] N Testemitanu State Univ Med & Pharm, Dept Infect Dis, Kishinev, Moldova

[3] Toma Ciorba Infect Clin Hospita, Kishinev, Moldova

[4] Natl Genet Inst, Los Angeles, CA USA

[5] Univ Klinikum Essen, Inst Virol, Essen, Germany

[6] Tech Univ Munich, Inst Virol, Munich, Germany

来源：

HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1848

引用

页码：912A / 912A

页数：1

共 38 条

[1] One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
Bazinet, M.
Pantea, V.
Cebotarescu, V.
Cojuhari, L.
Jimbei, P.
Krawczyk, A.
Vaillant, A.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S96 - S97
[2] Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV/HDV co-infection in Caucasian patients
Bazinet, Michel
Pantea, Victor
Cebotarescu, Valentin
Cojuhari, Lilia
Jimbei, Paulina
Albrecht, Jeffrey
Schmid, Peter
Karimzadeh, Hadi
Roggendorf, Michael
Vaillant, Andrew
HEPATOLOGY, 2015, 62 : 222A - 222A
[3] UPDATE ON THE SAFETY AND EFFICACY OF REP 2139 MONOTHERAPY AND SUBSEQUENT COMBINATION THERAPY WITH PEGYLATED INTERFERON ALPHA-2A IN CAUCASIAN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION
Bazinet, M.
Pantea, V.
Cebotarescu, V.
Cojuhari, L.
Jimbei, P.
Albrecht, J.
Schmid, P.
Krawczyk, A.
Karimzadeh, H.
Roggendorf, M.
Vaillant, A.
JOURNAL OF HEPATOLOGY, 2016, 64 : S584 - S585
[4] ONGOING ANALYSIS OF FUNCTIONAL CONTROL / CURE OF HBV AND HDV INFECTION FOLLOWING REP 2139-CA AND PEGYLATED INTERFERON ALPHA-2a THERAPY IN PATIENTS WITH CHRONIC HBV / HDV CO-INFECTION: 3-YEAR FOLLOW-UP RESULTS FROM THE REP 301-LTF STUDY
Bazinet, Michel
Pantea, Victor
Cebotarescu, Valentin
Cojuhari, Lilia
Jimbei, Pavlina
Krawczyk, Adalbert
Dittmer, Ulf
Vaillant, Andrew
HEPATOLOGY, 2019, 70 : 440A - 440A
[5] Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study
Bazinet, M.
Pantea, V.
Cebotarescu, V.
Cojuhari, L.
Jimbei, P.
Vaillant, A.
JOURNAL OF HEPATOLOGY, 2018, 68 : S509 - S509
[6] REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV/HDV co-infection
Bazinet, M.
Pantea, V.
Cebotarescu, V.
Cojuhari, L.
Jimbei, P.
Vaillant, A.
JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 5 - 6
[7] SIGNIFICANT REDUCTION OF HBsAg AND HDVRNA BY THE NUCLEIC ACID POLYMER REP 2139 IN CAUCASIAN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION
Bazinet, M.
Pantea, V.
Cebotarescu, V.
Cojuhari, L.
Jimbei, P.
Vaillant, A.
JOURNAL OF HEPATOLOGY, 2015, 62 : S257 - S258
[8] Update on safety and efficacy in the REP 401 protocol: REP 2139-Mgor REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naive caucasian patients with chronic HBeAg negative HBV infection
Bazinet, M.
Pantea, V.
Placinta, G.
Moscalu, I.
Cebotarescu, V.
Cojuhari, L.
Jimbei, P.
Iarovoi, L.
Smesnoi, V.
Musteata, T.
Jucov, A.
Krawczyk, A.
Vaillant, A.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S256 - S257
[9] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment of naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open label, phase 2 trial
不详
CHIMICA OGGI-CHEMISTRY TODAY, 2018, 36 (02) : 54 - 55
[10] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Bazinet, Michel
Pantea, Victor
Cebotarescu, Valentin
Cojuhari, Lilia
Jimbei, Pavlina
Albrecht, Jeffrey
Schmid, Peter
Le Gal, Frederic
Gordien, Emmanuel
Krawczyk, Adalbert
Mijocevic, Hrvoje
Karimzadeh, Hadi
Roggendorf, Michael
Vaillant, Andrew
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 877 - 889

← 1 2 3 4 →